510(k) Report

510(k) · Cleared

Cleared

Revi System

K252391510(k) TraditionalCleared Dec 12, 2025134-day reviewClass II21 CFR 876.5305

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Bluewind Medical, Ltd. · QXM Implanted Tibial Electrical Urinary Continence Device

Cleared on Dec 12, 2025 as substantially equivalent to K240037 (Bluewind Medical, Ltd., 2024) after a 134-day review. Its family tree reaches back 2 generations to 2023.

Decided
Dec 12, 2025
Review
134 days
Class
Class II
Product code
QXM
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN220073 (2023). No later device cites it as a predicate yet.

  1. Root · 2 generations backDEN220073 Revi SystemBluewind Medical, Ltd. · 2023
  2. 1 generation backK240037 Revi™ SystemBluewind Medical, Ltd. · 2024
  3. This deviceK252391 Revi SystemBluewind Medical, Ltd. · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN220073Revi SystemBluewind Medical, Ltd.2023—
−1K240037Revi™ SystemBluewind Medical, Ltd.2024—
0 (this device)K252391Revi SystemBluewind Medical, Ltd.2025—
FIG. 1 — Lineage of K252391, 2023–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QXM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QXM device

  1. #1 K240037 Revi™ Systemscore 13.3 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K240037Revi™ System
Summary page 5
…able tibial electrical urinary continence device (21 CFR 876.5305) V. Classification: Class II VI. Product Code: QXM VII. Predicate Device: Revi System (K240037) Note: The predicate device has not been subject to a design-related recall VIII. Indications for Use The Revi Sys…
Bluewind Medical, Ltd.2024—

Also cleared against K240037: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 2 years and passes through 1 company; a new generation was cleared every 1.6 years on median.
  • None of the 2 ancestors has a recall.
  • 1 other device also cites its predicate K240037.

How does its category compare?

All QXM devices

QXM Implanted Tibial Electrical Urinary Continence Device: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · QXM

1in 2025

2023: 12024: 12025: 12026 (partial year): 1
2007high 1 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QXM

Too few QXM 510(k)s in any year since 2007 to give a median.

Recalls per year · QXM

No recall names QXM since 2007.

Adverse event reports per year · QXM

17in 2025

2024: 42025: 17
2007high 17 (2025) · low 0 (2007)2025

MAUDE reports naming product code QXM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20231—00
20241—04
20251—017
20261—0—

What is it indicated for?

The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K252391: Revi System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K252391

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026